AU7286887A - Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof - Google Patents

Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof

Info

Publication number
AU7286887A
AU7286887A AU72868/87A AU7286887A AU7286887A AU 7286887 A AU7286887 A AU 7286887A AU 72868/87 A AU72868/87 A AU 72868/87A AU 7286887 A AU7286887 A AU 7286887A AU 7286887 A AU7286887 A AU 7286887A
Authority
AU
Australia
Prior art keywords
human
manufacture
directed against
antibody preparation
complement factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72868/87A
Inventor
S.I. Bo Nilsson
Ulf R. Nilsson
Karl-Erik Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nilsson Sib
Nilsson Ur
Svensson K
Original Assignee
Nilsson S I B
Nilsson U R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nilsson S I B, Nilsson U R filed Critical Nilsson S I B
Publication of AU7286887A publication Critical patent/AU7286887A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU72868/87A 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof Abandoned AU7286887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8601644 1986-04-11
SE8601644A SE452065B (en) 1986-04-11 1986-04-11 ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING

Publications (1)

Publication Number Publication Date
AU7286887A true AU7286887A (en) 1987-11-09

Family

ID=20364149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72868/87A Abandoned AU7286887A (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof

Country Status (5)

Country Link
EP (1) EP0263161A1 (en)
JP (1) JPS63503089A (en)
AU (1) AU7286887A (en)
SE (1) SE452065B (en)
WO (1) WO1987006344A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
AU2001234925A1 (en) * 2000-02-08 2001-08-20 The University Of Virginia Patent Foundation Methods for the prevention and treatment of infections using anti-C3b(i) antibodies
US6998243B2 (en) 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US20020160434A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons
US20020160532A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
US7049397B2 (en) * 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US20040224423A1 (en) * 2001-04-30 2004-11-11 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US6593298B2 (en) * 2001-04-30 2003-07-15 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US6602855B2 (en) * 2001-04-30 2003-08-05 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
CL2008003241A1 (en) * 2007-11-02 2009-07-31 Novartis Ag Binding molecule comprising an antigen-binding portion that binds to a c3b neoepitope; pharmaceutical composition comprising it; and its use to treat eye disorders
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
JP2013524213A (en) * 2010-03-31 2013-06-17 アナマー エービー How to detect tissue degradation leading to inflammation
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB2117514B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Polyvalent antiglobulin reagent
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation

Also Published As

Publication number Publication date
SE8601644D0 (en) 1986-04-11
EP0263161A1 (en) 1988-04-13
JPS63503089A (en) 1988-11-10
SE452065B (en) 1987-11-09
WO1987006344A1 (en) 1987-10-22
SE8601644L (en) 1987-10-12

Similar Documents

Publication Publication Date Title
AU599400B2 (en) Titanocenes and their use
AU626396B2 (en) Composition and use
GB2195632B (en) 4,6-orthoesters of sucrose and their use in the preparation of sucrose-6-acylates
AU7286887A (en) Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
EP0343526A3 (en) Novel polymer and its preparation and use
AU633294B2 (en) Motilin-like polypeptide and use thereof
AU3577489A (en) Brush and method in the manufacture thereof
AU3502789A (en) Composition and use
AU6292286A (en) N-substituted-3,4,5,6,-tetrahydrophthalimides, their preparation and use
AU8142287A (en) Fluoroalkoxyaluminum compounds and their use in polymerization processes
AU591579B2 (en) Antibodies for use in determining human glycoalbumin
AU555675B2 (en) Aminopropylpivalamides and their use in making 2-6-butyl- 1,4,5,6-tetrahydropyrimidine
IL92281A0 (en) Polyimidesiloxanes,their preparation and use
AU647559B2 (en) Pyrimidinyl- and triazinyl-salicylamides and their use and preparation
AU587646B2 (en) 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones and their use as antidepressants
GR890100860A (en) Composition based on trimebutyne and preparation process
AU2192783A (en) 3:,5:-diarabinosides preparation and application in therapy
AU8129987A (en) Pyrrolo-benzimidazoles, their preparation and use
IT1238207B (en) VITAMINIZED PREPARATION CONTAINING THE ENZYME LYZYZE USABLE IN ZOOTECHNICS AND PROCEDURE FOR ITS PRODUCTION.
AU8268887A (en) Aminoethylisoxazolidines, their preparation and use
AU4496089A (en) Aryloxyaldehydes and their manufacture
AU6638290A (en) Improvements in and relating to duckboards
ZA897772B (en) Organotinfluorides and their manufacture
AU8260287A (en) N-phenyl-N-carboxythioureas and their use in the control of pests
AU7418587A (en) Hapten-avidin complexes and their use in immunoassay